BRENDA CHALOUX: Open Payments
NPI 1588113328 · PITTSFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,387 in 14 payments from 10 companies in 2025. Trend: 2023 $671 · 2024 $1,861 · 2025 $1,387
Food & beverage: $1,387
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $319 |
| Neurocrine BioSciences, Inc. | 3 | $291 |
| Madrigal Pharmaceuticals | 1 | $146 |
| Lilly USA, LLC | 1 | $113 |
| ABBVIE INC. | 1 | $110 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $105 |
| Ultragenyx Pharmaceutical Inc. | 1 | $97 |
| GENZYME CORPORATION | 1 | $74 |
| Calliditas Therapeutics US Inc. | 1 | $71 |
| Axsome Therapeutics, Inc. | 1 | $61 |
Products named: INGREZZA, Wegovy, REZDIFFRA, ZEPBOUND, SKYRIZI, Ozempic, NEFFY, FABRAZYME.
Industry payments across MA — which companies pay providers there.
